Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Vectorbuilder Inc
Vectorbuilder Inc
Activities:
Research & Development
Revolutionise gene delivery from research to therapy
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Why has gene delivery become such a hot property?
VectorBuilder's latest cash injection drives them towards a CDMO facility for the manufacturing of plasmids, mRNA, AAV, lentivirus, cell lines, and a variety of viral and non-viral vectors
Manufacturing
Plasmid and lentiviral vector CDMO VectorBuilder orders rise by 70%
The company's plasmid and lentiviral vector CDMO products have received Investigational New Drug (IND) approval from the FDA
Research & Development
VectorBuilder to construct R&D and manufacturing campus
Construction is expected to cost $500m and will be split into two phases over the next four years
Subscribe now